MedTrace Logo

nVNS, CBD, and SoC for Persistent Post-Traumatic Headache

NCT07624279 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-06-03

No results posted yet for this study

Summary

Do cannabidiol (CBD) or vagus nerve stimulation reduce the frequency of persistent post-traumatic headache more than traditional oral headache medications?

Conditions

  • Persistent Post Traumatic Headache

Interventions

DEVICE

Non-Invasive Vagus Nerve Stimulation

Two treatments to the cervical vagus nerve twice daily

DRUG

Cannabidiol

Dosage titrated as per schedule

DRUG

Standard of Care

Oral pharmacotherapy as selected by site investigator and participant

Sponsors & Collaborators

  • National Football League

    collaborator OTHER

  • American Society of Pain and Neuroscience, Inc.

    lead OTHER

Principal Investigators

  • Nathaniel M Schuster, MD · University of California, San Diego

  • Erika A Petersen, MD · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-07-31
Completion
2028-07-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07624279 on ClinicalTrials.gov